Identification of specific autoantigens in Sjogren's syndrome by SEREX
Identification of specific autoantigens in Sjogren's syndrome by SEREX
复制标题
DOI：
10.1111/j.1365-2567.2005.02197.x
复制
发表时间：
2005-09-01
期刊：
影响因子：
6.4
通讯作者：
Kozaki, K
中科院分区：
文献类型：
--
作者：
Uchida, K;Akita, Y;Kozaki, K
我们进行了SEREX（抗原的血清学分析重组cDNA表达克隆）与Sjogren综合征（SjS）患者的血清和调查的频率对自身抗原的SEREX确定的自身抗体在健康人（HI）和SjS，类风湿性关节炎（RA）和系统性红斑狼疮（SLE）患者的血清中。SEREX结果显示，IFI 16和两个kelch样蛋白KLHL 12和KLHL 7是日本血吸虫的新的自身抗原。抗IFI 16自身抗体在SjS患者血清中的阳性率明显增高（SjS 70%，RA 13%，SLE 33%，HI 0%）。有趣的是，来自SjS的所有血清样品均表现出针对IFI 16和SS-B/La中的一种或两种的免疫反应性。血清中抗KLHL 12和KLHL 7自身抗体的存在对SjS具有显著特异性（分别为23%和17%），因为它们在RA、SLE或HI中未检测到。此外，我们证实，这些自身抗原的转录本表达优先在唾液腺和免疫赦免睾丸。我们的研究结果表明，这些自身抗原可能是有用的血清学标志物，为SjS的临床诊断，并可能发挥重要作用，作为器官特异性自身抗原的病因学SjS。本研究保证了抗IFI 16、KLHL 12和KLHL 7自身抗体与抗SS-B/La自身抗体组合的临床评价。
We carried out SEREX (serological analysis of antigens by recombinant cDNA expression cloning) using sera from patients with Sjogren's syndrome (SjS) and investigated the frequencies of autoantibodies against autoantigens identified by SEREX in the sera of healthy individuals (HI) and patients with SjS, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). IFI16 and two kelch-like proteins, KLHL12 and KLHL7, were found to be novel autoantigens in SjS by SEREX. A markedly high frequency of anti-IFI16 autoantibodies was observed in the sera of SjS (SjS, 70%; RA, 13%; SLE, 33%; HI, 0%). Interestingly, all serum samples from SjS demonstrated immunoreactivity against one or both of IFI16 and SS-B/La. The presence of autoantibodies against KLHL12 and KLHL7 in the sera was significantly specific to SjS (23% and 17%, respectively), as they were not detected in RA, SLE or HI. Furthermore, we confirmed that transcripts of these autoantigens were expressed preferentially in the salivary glands and immuno-privileged testes. Our results suggest these autoantigens may be useful as serological markers for the clinical diagnosis of SjS and may play a crucial role as organ-specific autoantigens in the aetiopathogenesis of SjS. This study warranted clinical evaluations of autoantibodies against IFI16, KLHL12 and KLHL7 in combination with anti-SS-B/La autoantibodies.